NCT07409090
Micro-Coring® for the Treatment of Skin Laxity of the Knees
Enrolling by Invitation
NAAges 22–70InterventionalTreatmentCytrellis Biosystems, Inc.
~12 participants
Updated 2026-02-13 on ClinicalTrials.gov
What's tested:Micro-Coring
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Correct identification of before and after treatment photos
Measured over 90 days
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male or female age 22 to 70
With lax skin over one or both knees, physician discretion
Able to provide written informed consent, understand and willing to comply with all study related procedures and follow-up visits
Fitzpatrick Skin Type I to VI as evaluated by the Investigator
Exclusion
Pregnant women or nursing mothers
Body mass index \> 30 · Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area
Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine
Patients with a history or presence of any clinically significant bleeding disorder
Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus
Patients with systemic infections or acute local skin infections (as Hepatitis disorders type A, B, C, D, E or F or HIV infection)
Patients who are on a high dose of anti-coagulants or blood-thinning substances, e.g., aspirin \> 150 mg/day, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days
Patients who are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area
Patients with have undergone surgery of the treatment area within last twelve (12) months, or have any scars less than twelve (12) months old in the treatment area
Patients who have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months
During the study time frame, unwilling to refrain from receiving these following aesthetic treatments within the same body region: toxin, filler, any skin resurfacing (laser, RF, ultrasound, microneedling, etc.);
Are currently enrolled in, or have overlapping participation in, another clinical trial outside of Cytrellis that includes treatment to the study area.
Unwilling to have photography taken for the study purpose
Any physical or psychological factors, in the judgment of the study investigator, may prevent subject from adhering to the study requirement correctly.
History of keloid formation or hypertrophic scarring
Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment and for the duration of the study
What this trial measures
- Correct identification of before and after treatment photos90 days
The baseline photos (before) taken before the procedure, and 90-day post procedure visit photos (after) are randomized and presented to a panel of three blinded photographic evaluators. Study success is defined as 75% subjects or more show an improvement as agreed upon by a least two out of three evaluators.